Bortezomib: A valuable new antineoplastic strategy in multiple myeloma

Acta Oncologica

Volumn 44, Issue 5, 2005, Pages 440-448

  Bladé, Joan ^a   Cibeira, M Teresa ^a   Rosiñol, Laura ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRINOTECAN; MELPHALAN; MITOXANTRONE; PREDNISONE; PROTEASOME; SARCOLYSIN; SOMATOMEDIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CELL ADHESION; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FATIGUE; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPONATREMIA; MALAISE; MAXIMUM TOLERATED DOSE; MULTIPLE DRUG DOSE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TOXIC HEPATITIS; TUMOR LYSIS SYNDROME; VOMITING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 23944453096     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510030002     Document Type: Review

References (50)

1. Bladé J, Vesale DH, Gertz MA. Transplantation for multiple myeloma: who, when, how often? Blood 2003;102:3469-77.
2. Matthews W, Driscoll J, Tanaka K, Ichihara A, Goldberg AL. Involvement of the proteasome in various degradative processes in mammalian cells. Proc Natl Acad Sci USA 1989;86:2597-601.
3. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
4. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29(suppl 1):3-9.
5. Wolf DH, Hilt W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta 2004;1695:19-31.
6. Delcros JG, Floc'h MB, Prigent C, Arlot-Bonnemains Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Curr Med Chem 2003;10:479-503.
7. Kettner CA, Shenvi AB. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J Biol Chem 1984;259:15106-14.
8. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
9. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
10. Nix D, Ryan DP, Eder JP, Fidias P, Guerciolini R, Sao N, et al. Pharmacokinetics of gemcitabine and the proteasome inhibitor bortezomib (formerly PS-341) in adult patients with solid malignancies. Proc Am Assoc Cancer Res 2003;44:1061.
11. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Huntingt) 2004;18:14-21.
12. VELCADE (bortezomib) for injection. Prescribing information available at http://www millennium com/products/velcade/index asp.
13. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
14. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
15. Supko JG, Eder JP, Lynch TJ, Belonogovna N, Guerciolini R, Cusack JC, et al. Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies. Proc Am Soc Clin Oncol 2003;22:136.
16. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
17. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
18. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
19. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
20. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
21. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
22. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
23. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
24. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
25. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
27. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: An update with additional follow-up. Hematol J 2004;5(suppl 2):S103-4.
28. Lee S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Jagannath S, et al. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 2003;22:582.
29. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
30. Berenson JR, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, et al. The safety of prolonged therapy with the proteasome inhibitor bortezomib (VELCADE) in relapsed and/or refractory multiple myeloma (MM). Hematol J 2004;5(suppl 2):S129.
31. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T, et al. Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. Available at: http://www abstracts2view com/hem_sandiego2004/ 2004;104:abstract 336.5.
32. Berenson J, Yang H, Swift R, Sadler K, Vescio R, Adams J, et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood 2004;104:64a.
33. Zangari M, Barlogie B, Hollmig K, Fassas A, Rasmussen E, Thertulien R, et al. Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood 2004;104:413a.
34. Hollmig K, Stover J, Talamo G, Fassas R, Lee CK, Anaissie E, et al. Bortezomib (Velcade)+Adriamycin+ Thalidomide+Dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood 2004;104:659a.
35. Chanan-Khan AA, Miller KC, McCarthy P, DiMiceli LA, Yu J, Bernstein ZP, et al. A phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients with relapsed or refractory multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM): encouraging preliminary results. Blood 2004; 104:665a.
36. Jagannath S, Richardson P, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc Am Soc Clin Oncol 2003;22:582.
37. Zangari M, Barlogie B, Jacobson J, Rasmussen E, Burns M, Kordsmeier B, et al. VTD regimen comprising Velcade (V)+thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003;102:236a.
38. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-65.
39. Richardson PG, Chanan-Khan A, Schlossman RL, Munshi NC, Wen P, Briemberg H, et al. Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma (MM). Blood 2004;104:100a.
40. Jagannath S, Durie B, Wolf JL, Camacho E, Irwin D, Lutzky J, et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. Blood 2004;104:98a-9a.
41. Harousseau J, Attal M, Leleu X, Gressin R, Hulin C, Fuzibet JG, et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. Blood 2004;104:416a.
42. Cavenagh J, Popat R, Curry N, Stec J, Morris TC, Drake M, et al. PAD combination therapy (PS-341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2004;104:413a.
43. Alexanian R, Wang LW, Weber DM, Delasalle KB. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood 2004;104:64a.
44. Mateos MV, Bladé J, Diaz Mediavilla J, Lahuerta JJ, Terol MJ, Hernández J, et al. A phase I/II national, multicenter, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Blood 2004;104:943a.
45. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, et al. Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma. Hematol J 2004;5(suppl 2): S130-1.
46. Richardson P, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, et al. Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 2003;102:149a.
47. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004;130:623-5.
48. Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, et al. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003; 102:386b.
49. Rosiñol L, Montoto S, Cibeira MT, Bladé J. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005;165:464-5.
50. Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-6.